NCT01943045View on ClinicalTrials.gov

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Diabetes Mellitus
Interventions
BIOLOGICAL

NGM282

OTHER

Placebo

Trial Locations (9)

Unknown

NGM Clinical Study Site 6103, Melbourne

NGM Clinical Study Site 6104, Melbourne

NGM Clinical Study Site 6101, Perth

NGM Clinical Study Site 6403, Auckland

NGM Clinical Study Site 6405, Auckland

NGM Clinical Study Site 6401, Christchurch

NGM Clinical Study Site 6406, Dunedin

NGM Clinical Study Site 6404, Tauranga

NGM Clinical Study Site 6402, Wellington

Sponsors
All Listed Sponsors
collaborator

NGM Biopharmaceuticals Australia Pty Ltd

INDUSTRY

lead

NGM Biopharmaceuticals, Inc

INDUSTRY

NCT01943045 - Phase 2 Study of NGM282 in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter